US 12,274,711 B2
Method of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors
Tatiana I. Vener, Stirling, NJ (US); Carlo C. Derecho, Lakehurst, NJ (US); John F. Palma, Alamo, CA (US); and Mical Raponi, San Francisco, CA (US)
Assigned to Janssen Pharmaceutica NV, Beerse (BE)
Filed by Janssen Pharmaceutica NV, Beerse (BE)
Filed on Dec. 28, 2022, as Appl. No. 18/147,134.
Application 18/147,134 is a division of application No. 13/750,258, filed on Jan. 25, 2013, granted, now 11,559,540.
Application 13/750,258 is a continuation of application No. PCT/US2011/045693, filed on Jul. 28, 2011.
Claims priority of provisional application 61/368,453, filed on Jul. 28, 2010.
Prior Publication US 2023/0270769 A1, Aug. 31, 2023
Int. Cl. C12Q 1/68 (2018.01); A61K 31/4709 (2006.01); A61K 31/7048 (2006.01); C12Q 1/6886 (2018.01)
CPC A61K 31/7048 (2013.01) [A61K 31/4709 (2013.01); C12Q 1/6886 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01); C12Q 2600/158 (2013.01); C12Q 2600/16 (2013.01)] 12 Claims
 
1. A method for prescribing tipifarnib to a subject diagnosed with a disorder, the method comprising:
evaluating expression of RAS guanyl releasing protein 1 (RASGRP1) and aprataxin (APTX) in a blood sample of said subject by using a polymerase chain reaction to achieve an amplification of signals from ribonucleic acid targets using at least one primer from the group consisting of
 
 (i) 5′-CGCTTCCGATTGGGCTAC-3′
 
 
 
 (ii) 5′-AGAATCAAAATCCTGGCTGATC-3′
 
 
 
 (iii) 5′-CTGGACGATCTCATTGACAGC-3′
 
 and
 
 
 
 (iv) 5′-CTTGCAACAGTTGGTTACTTCG-3′.